53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04252209 (ClinicalTrials.gov) | August 2021 | 26/1/2020 | the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia | the Effect of Mixture of Natural Products As Salivary Substitute In Comparison To Carboxy Methyl Cellulose In Treatment Of Xerostomia In Patients With Sjogren's Syndrome: Cross Over Randomized Clinical Trial | Sjogren's Syndrome;Xerostomia | Other: natural herbs of coconut, aloe vera, and pepperint;Other: carboxy methyl cellulose | Cairo University | NULL | Not yet recruiting | 18 Years | 80 Years | All | 44 | Phase 3 | NULL |
| 2 | NCT01759108 (ClinicalTrials.gov) | March 13, 2020 | 23/12/2012 | Rebamipide AND Sjögren Syndrome | Rebamipide for the Treatment of Xerostomia in Sjögren Syndrome | Improving Symptoms of Dry Mouth in Sjogren's Syndrome | Drug: Rebamipide | University of Alexandria | NULL | Recruiting | N/A | N/A | All | 55 | N/A | Egypt |
| 3 | JPRN-UMIN000010710 | 2013/05/15 | 15/05/2013 | Effective treatment of rebamipide on xerostomia in Sjogrens syndrome patients:a pilot study -a double-blind placebo-controlled trial- | Xerostomia in Sjogrens syndrome | Rebamipide was administered orally at 100 mg each time three times a day after meals for 8 weeks. Placebo was administered orally three times a day after meals for 8 weeks. | Tochigi medical center | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 60 | Phase 2 | Japan | |
| 4 | NCT03578900 (ClinicalTrials.gov) | January 1, 2013 | 18/5/2018 | Quality of Life and Sjögren Syndrome | Quality of Life in a Portuguese Population With Primary Sjögren Syndrome | Xerostomia;Hyposalivation;Quality of Life;Sjogren's Syndrome | Drug: Xeros;Drug: Citric Acid based Mouthwash | Grupo de Investigação em Bioquímica e Biologia Oral | University of Lisbon;Portuguese Institute of Rheumatology;Dentaid SL | Completed | 18 Years | N/A | All | 289 | Phase 4 | NULL |
| 5 | NCT01647737 (ClinicalTrials.gov) | March 2011 | 14/5/2012 | Green Tea Lozenges for the Management of Dry Mouth | A Natural Formulation for Patients Diagnosed With Xerostomia | Xerostomia;Sjogren Syndrome;Dry Mouth | Dietary Supplement: MighTeaFlow;Dietary Supplement: Xylitol | Augusta University | GlaxoSmithKline | Completed | 18 Years | 75 Years | All | 60 | Phase 1/Phase 2 | United States |
| 6 | NCT01369589 (ClinicalTrials.gov) | November 2010 | 6/6/2011 | An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness | An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome | Xerostomia;Sjogren's Syndrome | Drug: P-552;Drug: Placebo | Parion Sciences | NULL | Completed | 18 Years | N/A | All | 24 | Phase 1/Phase 2 | United States |
| 7 | NCT00637793 (ClinicalTrials.gov) | February 2008 | 11/3/2008 | Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome | A Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's Syndrome | Xerostomia;Sjogren's Syndrome | Drug: NGX267 | TorreyPines Therapeutics | NULL | Completed | 21 Years | 55 Years | Both | 24 | Phase 2 | United States |
| 8 | JPRN-UMIN000000997 | 2008/01/01 | 28/01/2008 | The non-blind test crossover controlled trial how we used a physically unimpaired person volunteer about quantity of salivary secretion increase action of gargle remedy of cevimeline hydrochloride hydrate | Xerostomia due to Sjogren`s syndrome | It is a gargle with a test drug(Cevimeline hydrochloride hydrate 30mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo1 (Cevimeline hydrochloride hydrate 9mg+Hachiazule(TM)gargle 2g+distilled water 50cc)for two minutes. wash out, It is a gargle with false placebo2 (Hachiazule(TM)gargle2g+distilled water 50cc)for two minutes. It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes. It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo1 for two minutes. It is a gargle with a test drug for two minutes. wash out, It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes. It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes. wash out,It is a gargle with false placebo2 for two minutes. It is a gargle with false placebo2 for two minutes. wash out, It is a gargle with false placebo1 for two minutes. wash out, It is a gargle with a test drug for two minutes. | Department of Dentistry and Oral Surgery, Tochigi National Hospital | National Institute of Public Health | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 12 | Phase 1 | Japan | |
| 9 | NCT00438048 (ClinicalTrials.gov) | November 2006 | 20/2/2007 | A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment | Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva | Primary Sjogren;Secondary Sjogren;Xerostomia | Procedure: pilocarpine;Drug: Artificial Saliva | Pontificia Universidad Catolica de Chile | Formulario MAgistral Farmacias Ahumada | Completed | 18 Years | N/A | Both | 76 | Phase 4 | Chile |
| 10 | NCT00233363 (ClinicalTrials.gov) | March 2005 | 4/10/2005 | Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome | An Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s Syndrome | Xerostomia;Sjogren's Syndrome | Drug: Rebamipide | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | 100 | Phase 2 | Japan |